(b) Explain one advantage and one disadvantage for CH of having a mission statement. (c) Explain two possible external sources of finance CH could use to continue production of Copper Health (CH) was the market leader in the production of anti-venom vaccines to treat poisonous snake bites. CH's mission - influenced heavily by corporate social responsibility (CSR) - is to put customers first and profits second in the treatment of snake bites. lth (CH) recently announced that it will no longer produce anti-venom vaccines. Several large Mexican, Despite 100000 deaths worldwide each year from snake bites and 400000 serious injuries, CH Brazilian and Indian pharmaceutical companies have entered the market selling anti-venom vaccines at a much lower price than CH. A spokesperson for CH said: We will remain a private limited company where corporate social responsibility (CSR) remains an important driving force for our mission. Our medical research is only financed from retained profit. When the lower-priced competition arrived, our sales and profits of anti-venom vaccines decreased significantly. Treating snakebites no longer makes financial sense. Instead, the technology used to produce anti-venom vaccines will be used to research and develop (R&D) other life-saving vaccines". A non-governmental organization (NGO) has demanded action. "CH is the largest manufacturer of anti-venom vaccines in the world. Although CH's competitors are increasing their production of anti-venom vaccines they will not be able to produce enough to satisfy demand for the next two years. There will be a major shortage. This will result in many life- threatening injuries and deaths." The non-governmental organization (NGO) has unged CH to seek new sources of finance to continue the production of the anti-venom vaccine. (Source O Intermational taccalsureate Organiation 2019 anti venom: a medication made from antibodies that is used to treat venomous bites and stings (a) Define the term retained profit. anti-venom vaccines. (d) Discuss CH's decision to stop producing anti-venom vaccines,